Drug General Information (ID: DDI56V31KM)
Drug Name			Methazolamide		Drug Info		Eslicarbazepine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Carbonic Anhydrase Inhibitors				Anticonvulsants
Structure

Mechanism of Methazolamide-Eslicarbazepine Interaction (Severity Level: Moderate)
Increased risk of hyponatremia Click to Show/Hide Mechanism Graph
Drug Name		Methazolamide				Eslicarbazepine
Mechanism		Hyponatremia				Hyponatremia
Key Mechanism Factor 1
		Factor Name		Hyponatremia
		Factor Description		Hyponatremia is a condition in which the amount of sodium in the blood is lower than normal. Symptoms of hyponatremia may include: nausea and vomiting, fatigue, headache or confusion, muscle cramps, weakness, irritability and restlessness.
Mechanism Description		Increased risk of hyponatremia by the combination of Methazolamide and Eslicarbazepine

Recommended Action
Management		Routine monitoring of serum sodium and chloride levels should be considered during maintenance treatment with eslicarbazepine acetate and concomitant use of other medications known to decrease serum sodium levels. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Depending on the severity of hyponatremia, dosage reduction or discontinuation of eslicarbazepine acetate and other medications may be required, and appropriate medical intervention instituted as necessary.

References
1	Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.